Skip to main content

PerkinElmer Value Stock - Dividend - Research Selection

Perkinelmer

ISIN: US7140461093 , WKN: 850943

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


3 Cash-Producing Stocks That Concern Us

2025-12-29
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Q3 Earnings Highlights: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks

2025-12-23
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Revvity (NYSE:RVTY) and the rest of the research tools & consumables stocks fared in Q3.

Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica

2025-12-19
RVTY unveils Signals Xynthetica, an AI-augmented design platform that links predictive models with real lab data to speed discovery.

Revvity to Present at J.P. Morgan Healthcare Conference

2025-12-18
WALTHAM, Mass., December 18, 2025--Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT.

Revvity, Inc. (NYSE:RVTY) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

2025-12-18
Revvity (NYSE:RVTY) has had a great run on the share market with its stock up by a significant 10% over the last three...

3 Reasons RVTY is Risky and 1 Stock to Buy Instead

2025-12-18
Revvity currently trades at $96.77 per share and has shown little upside over the past six months, posting a middling return of 2.5%. The stock also fell short of the S&P 500’s 13.6% gain during that period.

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

2025-12-16
WALTHAM, Mass., December 16, 2025--Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in‑silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and r

Barclays Maintains Revvity (RVTY) Overweight Recommendation

2025-12-16

How Is Revvity's Stock Performance Compared to Other Health Care Stocks?

2025-12-15
Revvity has underperformed the Health Care industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Goldman Sachs Initiates Coverage of Revvity (RVTY) with Neutral Recommendation

2025-12-10